Univariate logistic regression analysis for potential predictors of infusion reaction
| Variables | Estimates | SE | OR | p Value |
|---|---|---|---|---|
| Age (years) | −0.02 | 0.02 | 0.98 | 0.37 |
| Gender (female vs male) | 0.24 | 0.40 | 1.62 | 0.55 |
| Duration (years) | 0.04 | 0.03 | 1.04 | 0.12 |
| DAS28 | 0.08 | 0.21 | 1.08 | 0.69 |
| CRP (mg/dl) | 0.01 | 0.08 | 1.01 | 0.87 |
| MMP-3 (per 10 ng/ml) | −0.01 | 0.01 | 0.99 | 0.55 |
| HAQ-DI | −0.12 | 0.39 | 0.89 | 0.75 |
| RF (per 10 IU/ml) | 0.01 | 0.00 | 1.00 | 0.14 |
| ANA (×) | 0.00 | 0.00 | 1.00 | 0.46 |
| MTX (mg/week) | 0.03 | 0.09 | 1.03 | 0.77 |
| MTX duration (months) | 0.00 | 0.01 | 1.00 | 0.72 |
| Use of glucocorticoids | −0.63 | 0.28 | 0.53 | 0.03* |
| Dose of prednisolone (mg/day) | −0.13 | 0.09 | 0.88 | 0.14 |
| FCGR3A V/V+V/F vs F/F | 0.11 | 0.27 | 1.12 | 0.67 |
| FCGR3B NA1/1 vs NA1/2+2/2 | 0.86 | 0.31 | 2.37 | <0.01* |
ANA, antinuclear antibody; CRP, C reactive protein; DAS28, 28-joint Disease Activity Score; HAQ-DI, Health Assessment Questionnaire-Disease Index; MMP, matrix metalloproteinase; MTX, methotrexate; RF, rheumatoid factor.